
|Articles|May 21, 2019
Xcenda Announces Acquisition of Dymaxium
Advertisement
Xcenda, a part of AmerisourceBergen, has acquired Dymaxium, a market access partner specializing in the exchange of evidence and information between payers and life science companies.
This acquisition will further simplify and streamline the necessary communication of clinical evidence and health economic information between manufacturers and population health decision makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Parabilis Medicines Raises $670 Million in Initial Public Offering
2
Pharmaceutical Executive Daily: Parabilis Medicines Prices Record-Breaking $670 Million IPO
3
What 10 Years of Clinical Research Growth in Puerto Rico Have Taught Us
4
The Regulatory Landscape for Rare Pediatric Diseases
5




